| Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction X Liu, Y Wang, H Lu, J Li, X Yan, M Xiao, J Hao, A Alekseev, H Khong, ... Nature 567 (7749), 525-529, 2019 | 359 | 2019 |
| Adjuvants for peptide-based cancer vaccines H Khong, WW Overwijk Journal for immunotherapy of Cancer 4, 1-11, 2016 | 170 | 2016 |
| Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation M Singh, H Khong, Z Dai, XF Huang, JA Wargo, ZA Cooper, JP Vasilakos, ... The Journal of immunology 193 (9), 4722-4731, 2014 | 167 | 2014 |
| Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy M Sharma, H Khong, F Fa’ak, SE Bentebibel, LME Janssen, BC Chesson, ... Nature communications 11 (1), 661, 2020 | 141 | 2020 |
| HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes RM Mbofung, JA McKenzie, S Malu, M Zhang, W Peng, C Liu, I Kuiatse, ... Nature communications 8 (1), 451, 2017 | 121 | 2017 |
| Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain M Singh, C Vianden, MJ Cantwell, Z Dai, Z Xiao, M Sharma, H Khong, ... Nature communications 8 (1), 1447, 2017 | 83 | 2017 |
| Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy Y Hailemichael, A Woods, T Fu, Q He, MC Nielsen, F Hasan, J Roszik, ... The Journal of clinical investigation 128 (4), 1338-1354, 2018 | 81 | 2018 |
| Fucosylation enhances the efficacy of adoptively transferred antigen-specific cytotoxic T lymphocytes G Alatrash, N Qiao, M Zhang, M Zope, AA Perakis, P Sukhumalchandra, ... Clinical Cancer Research 25 (8), 2610-2620, 2019 | 25 | 2019 |
| Preclinical immune response and safety evaluation of the protein subunit vaccine nanocovax for COVID-19 TNM Tran, BP May, TT Ung, MK Nguyen, TTT Nguyen, VL Dinh, CC Doan, ... Frontiers in Immunology 12, 766112, 2021 | 22 | 2021 |
| Peptide vaccine formulation controls the duration of antigen presentation and magnitude of tumor-specific CD8+ T cell response H Khong, A Volmari, M Sharma, Z Dai, CS Imo, Y Hailemichael, M Singh, ... The Journal of Immunology 200 (10), 3464-3474, 2018 | 20 | 2018 |
| Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial TP Nguyen, Q Do, LT Phan, DV Dinh, H Khong, LV Hoang, TV Nguyen, ... The Lancet Regional Health–Western Pacific 24, 2022 | 15 | 2022 |
| HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nat Commun 8: 451 RM Mbofung, JA McKenzie, S Malu, M Zhang, W Peng, C Liu, I Kuiatse, ... | 13 | 2017 |
| 31st annual meeting and associated programs of the society for immunotherapy of cancer (Sitc 2016): Part two: National harbor, md, USA. 9-13 November 2016 C Ager, M Reilley, C Nicholas, T Bartkowiak, A Jaiswal, M Curran, ... Journal for ImmunoTherapy of Cancer 4, 107-221, 2016 | 12 | 2016 |
| CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner L Huang, Z Wang, C Liu, C Xu, RM Mbofung, JA McKenzie, H Khong, ... Oncogene 36 (28), 4081-4086, 2017 | 11 | 2017 |
| The efficacy, safety and immunogenicity Nanocovax: results of a randomized, double-blind, placebo-controlled Phase 3 trial TP Nguyen, Q Do, LT Phan, DD Anh, H Khong, TV Nguyen, LV Hoang, ... medRxiv, 2022.03. 22.22272739, 2022 | 6 | 2022 |
| Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine TP Nguyen, Q Do, LT Phan, DV Dinh, H Khong, LV Hoang, TV Nguyen, ... medRxiv, 2021.07. 22.21260942, 2021 | 6 | 2021 |
| NKTR-214 enhances anti-tumor T cell immune responses induced by checkpoint blockade or vaccination M Sharma, F Fa’ak, L Janssen, H Khong, Z Xiao, Y Hailemichael J Immunother Cancer 5 (Suppl2; abstr P140), 86, 2017 | 4 | 2017 |
| Induction of potent systemic anti-melanoma immunity through intratumoral CD40 activation and checkpoint blockade M Singh, Z Dai, H Khong, C Vianden, M Cantwell, W Overwijk Journal for ImmunoTherapy of Cancer 3, 1-1, 2015 | 3 | 2015 |
| L-tyrosine is a promising cancer vaccine adjuvant H Khong, M Sharma, Z Dai, M Singh, Y Hailemichael, W Overwijk Journal for ImmunoTherapy of Cancer 3, 1-1, 2015 | 2 | 2015 |
| Reversing gp100/IFA-induced impairment of anti-CTLA-4 checkpoint blockade therapy Y Hailemichael, T Fu, H Khong, Z Dai, P Sharma, WW Overwijk Journal for ImmunoTherapy of Cancer 2, 1-2, 2014 | 1 | 2014 |
